|
|
 |
|
Viewing report
|
|
|
|
Postpartum Depression - Overcoming Unique Barriers to Treatment
Datamonitor, Sep 2002
Increasingly, healthcare systems are focusing on postpartum depression as a significant problem that is not currently being adequately addressed. Despite the fact that it has the potential to become a chronic, recurring disorder, it is still treated as a transitory illness, which not only raises the cost to society over the long-term but also impacts pharmaceutical revenues.Detailed analysis of the epidemiology of postpartum depression in 12 separate markets, including diagnosis and drug-treatment ratesIn-depth profiles of the current clinical data for postpartum depressionAnalysis of the unique problems facing manufacturers in this market, particularly the decision to opt for safety data as opposed to efficacy resultsOutline of the need to develop specific marketing campaigns for postpartum depression as it is treated by numerous secondary-care specialistsAn illustration of the value of the current postpartum depression market, including an outline of how the revenue potential can be increasedAlthough 15% of all women who give birth will suffer from postpartum depression, only 24% are actually diagnosed. This is a major barrier to treatment and needs to be addressed by both manufacturers and healthcare systems. Antidepressant manufacturers need to illustrate the range of problems caused by postpartum depression, from the impact on the development of the infant to the overall cost of depression to society, and lobby for enhanced screening programs.Wyeth’s Effexor and Eli Lilly’s Prozac are the leading drugs in terms of clinical research, highlighting the opportunity that exists for other antidepressant manufacturers. Most other manufacturers have only publicized safety data as concerns are held by physicians and patients about the potential transfer of antidepressant medication through breast milk. However, efficacy data is needed to ramp up the number of patients treated with antidepressant medication.Postpartum depression represents a significant commercial opportunity for smaller players in the antidepressant market as opposed to the major players. The size of the market is smaller than a number of anxiety disorder markets, which explains why the major manufacturers have concentrated on this area in recent years. However, the size of the depression market means that niche players have an opportunity to establish themselves and considerably enhance their revenue performance.Understand the key issues which have limited the size of the postpartum depression marketEnhance your ability to drive the growth of this market by targeting the appropriate medical specialistsDiscover what steps competing players have taken to break into the marketEvaluate the clear opportunities that exist in the postpartum depression market
Customers who bought this item also bought
Commercial Insight: Depression - Atypical lifecycle management strategy rejuvenates depression market
Pipeline Insight: Depression - Novel Drugs to Grow Third-line Market
Major Depression and Bipolar Disorder - Evaluation and Management
Pipeline Insight: Depression - Novel therapies key to market penetration
Drugs of Tomorrow 2002: Depression - A pipeline driven by side effect profile
Treatment-resistant depression: An untapped area of the patient population
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression
Drugs of Tomorrow 2001: Depression - A Future Away From Serotonin?
Depression Management Benchmarks: Trends in Integration of Behavioral and Physical Health
Forecast Insight: Depression - Generic Induced Brand Erosion Leads to Market Decline
Pipeline Insight: Bipolar Disorder - New Treatments for Bipolar Depression Set to Drive Near-term Growth
Strategic Perspectives 2001: Antidepressant Treatment Strategies - Efficacy Drives Psychiatrist Drug Choice
|
|
|
|
